TAVI Halo Shines On Embolic Protection Devices
This article was originally published in Start Up
Executive Summary
Transcatheter heart valve (TAVI) companies are hot. A market that was worth $20-$30 million just two or three years ago, based on devices with an average selling price of $23,000, was worth more than $400 million in 2010, and to date these products are only approved in Europe. A major stumbling block to widespread penetration exists however: the higher risk of stroke seen with TAVI as compared to surgical valve replacement. Thus, investors are spreading the net out further, to scoop up companies developing embolic protection devices, to solve some of the potential neuro problems that can result from TAVI.